Guardant Health Inc
Затворен
СекторЗдравеопазване
157.41 -0.3
Преглед
Промяна на цената на акция
24 ч
Минимум
156.16
Максимум
158.93
Приходи | -8.1M -120M |
|---|---|
Продажби | 33M 335M |
EPS | -0.89 |
Марж на печалбата | -35.866 |
Служители | 2,490 |
EBITDA | -8.1M -109M |
Следващи печалби | 28.10.2026 г. |
|---|
Пазарна капитализация | 2.4B 22B |
|---|---|
Предишно отваряне | 157.71 |
Предишно затваряне | 157.41 |
Настроения в новините
By Acuity
50%
50%
136 / 339 Класиране в Healthcare
Guardant Health Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Guardant Health Inc Прогноза
Настроение
By Acuity
136 / 339 Класиране в Здравеопазване
Настроения в новините
Neutral
Волатилност
Под средното
Обем новини (RCV)
Среден
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.